Cargando…
Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis
This study investigated the antispasticity potential of Sativex in mice. Chronic relapsing experimental allergic encephalomyelitis was induced in adult ABH mice resulting in hind limb spasticity development. Vehicle, Sativex, and baclofen (as a positive control) were injected intravenously and the “...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scholarly Research Network
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3423911/ https://www.ncbi.nlm.nih.gov/pubmed/22928118 http://dx.doi.org/10.5402/2012/802649 |
_version_ | 1782241162153689088 |
---|---|
author | Hilliard, A. Stott, C. Wright, S. Guy, G. Pryce, G. Al-Izki, S. Bolton, C. Giovannoni, G. |
author_facet | Hilliard, A. Stott, C. Wright, S. Guy, G. Pryce, G. Al-Izki, S. Bolton, C. Giovannoni, G. |
author_sort | Hilliard, A. |
collection | PubMed |
description | This study investigated the antispasticity potential of Sativex in mice. Chronic relapsing experimental allergic encephalomyelitis was induced in adult ABH mice resulting in hind limb spasticity development. Vehicle, Sativex, and baclofen (as a positive control) were injected intravenously and the “stiffness” of limbs assessed by the resistance force against hind limb flexion. Vehicle alone caused no significant change in spasticity. Baclofen (5 mg/kg) induced approximately a 40% peak reduction in spasticity. Sativex dose dependently reduced spasticity; 5 mg/kg THC + 5 mg/kg CBD induced approximately a 20% peak reduction; 10 mg/kg THC + 10 mg/kg CBD produced approximately a 40% peak reduction in spasticity. Sativex has the potential to reduce spasticity in an experimental mouse model of multiple sclerosis (MS). Baclofen reduced spasticity and served as a positive control. Sativex (10 mg/kg) was just as effective as baclofen, providing supportive evidence for Sativex use in the treatment of spasticity in MS. |
format | Online Article Text |
id | pubmed-3423911 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | International Scholarly Research Network |
record_format | MEDLINE/PubMed |
spelling | pubmed-34239112012-08-27 Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis Hilliard, A. Stott, C. Wright, S. Guy, G. Pryce, G. Al-Izki, S. Bolton, C. Giovannoni, G. ISRN Neurol Research Article This study investigated the antispasticity potential of Sativex in mice. Chronic relapsing experimental allergic encephalomyelitis was induced in adult ABH mice resulting in hind limb spasticity development. Vehicle, Sativex, and baclofen (as a positive control) were injected intravenously and the “stiffness” of limbs assessed by the resistance force against hind limb flexion. Vehicle alone caused no significant change in spasticity. Baclofen (5 mg/kg) induced approximately a 40% peak reduction in spasticity. Sativex dose dependently reduced spasticity; 5 mg/kg THC + 5 mg/kg CBD induced approximately a 20% peak reduction; 10 mg/kg THC + 10 mg/kg CBD produced approximately a 40% peak reduction in spasticity. Sativex has the potential to reduce spasticity in an experimental mouse model of multiple sclerosis (MS). Baclofen reduced spasticity and served as a positive control. Sativex (10 mg/kg) was just as effective as baclofen, providing supportive evidence for Sativex use in the treatment of spasticity in MS. International Scholarly Research Network 2012-08-07 /pmc/articles/PMC3423911/ /pubmed/22928118 http://dx.doi.org/10.5402/2012/802649 Text en Copyright © 2012 A. Hilliard et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Hilliard, A. Stott, C. Wright, S. Guy, G. Pryce, G. Al-Izki, S. Bolton, C. Giovannoni, G. Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis |
title | Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis |
title_full | Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis |
title_fullStr | Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis |
title_full_unstemmed | Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis |
title_short | Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis |
title_sort | evaluation of the effects of sativex (thc bds: cbd bds) on inhibition of spasticity in a chronic relapsing experimental allergic autoimmune encephalomyelitis: a model of multiple sclerosis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3423911/ https://www.ncbi.nlm.nih.gov/pubmed/22928118 http://dx.doi.org/10.5402/2012/802649 |
work_keys_str_mv | AT hilliarda evaluationoftheeffectsofsativexthcbdscbdbdsoninhibitionofspasticityinachronicrelapsingexperimentalallergicautoimmuneencephalomyelitisamodelofmultiplesclerosis AT stottc evaluationoftheeffectsofsativexthcbdscbdbdsoninhibitionofspasticityinachronicrelapsingexperimentalallergicautoimmuneencephalomyelitisamodelofmultiplesclerosis AT wrights evaluationoftheeffectsofsativexthcbdscbdbdsoninhibitionofspasticityinachronicrelapsingexperimentalallergicautoimmuneencephalomyelitisamodelofmultiplesclerosis AT guyg evaluationoftheeffectsofsativexthcbdscbdbdsoninhibitionofspasticityinachronicrelapsingexperimentalallergicautoimmuneencephalomyelitisamodelofmultiplesclerosis AT pryceg evaluationoftheeffectsofsativexthcbdscbdbdsoninhibitionofspasticityinachronicrelapsingexperimentalallergicautoimmuneencephalomyelitisamodelofmultiplesclerosis AT alizkis evaluationoftheeffectsofsativexthcbdscbdbdsoninhibitionofspasticityinachronicrelapsingexperimentalallergicautoimmuneencephalomyelitisamodelofmultiplesclerosis AT boltonc evaluationoftheeffectsofsativexthcbdscbdbdsoninhibitionofspasticityinachronicrelapsingexperimentalallergicautoimmuneencephalomyelitisamodelofmultiplesclerosis AT giovannonig evaluationoftheeffectsofsativexthcbdscbdbdsoninhibitionofspasticityinachronicrelapsingexperimentalallergicautoimmuneencephalomyelitisamodelofmultiplesclerosis |